Got called out from my covered call at a $10.00 strike price and I'm as happy as can be. I swore off this stock when I was in at 14.00 and it dropped to $10.00. I got greedy and I bought back in when the options were high in December and made good coin, just before expiration the stock plummeted to $5.50. #$%$?
It was a painful moment. That monday I felt robbed, but my decisions was to just hang in there and either go down with the ship or just hope it goes up. I was way under water with this stock and it was a huge hit to my cash account. Proud to say that with a few calls over the last few months and this rise back up to $10.00 I'm walking away with a pretty good gain. I have just 200 shares of stock left in this company and will leave them in case the big buy out that everyone is wishing for happens.
This was hands down the most frustrating stock I've ever owned, may come back when the price drops, doggy breath is rubbing it in and everyone is calling for managements head. Till then good luck!
I remember you and all names that you mentioned. Also I remember Ed, Art and Mg's mom I am sure I will think of more names after I click this. Great hearing from you!
BOSTON--(BUSINESS WIRE)--April 14, 2015--
Attorneys from Mintz, Levin,Cohn, Ferris,Glovsky and Popeo, P.C. represented ImmunoGen, Inc. in a $200 million non-dilutive royalty transaction with funds managed by TPG Special Situations Partners (TSSP).
In return for the payment to ImmunoGen, TSSP will have the right to receive 100% of the royalty revenue on Kadcyla commercial sales that would otherwise be paid by Roche to ImmunoGen until TSSP has received a total of either $235 million or $260 million, depending on timing. After this threshold is met, if ever, ImmunoGen will receive 85% of the Kadcyla royalty revenue and TSSP will receive 15% of the Kadcyla royalty revenue until this revenue stream ends.
don't forget that IMGN still gets milestone payments from the other partners. They only monetized the kadcyla revenue stream. I'm happy to see that IMGN is not a one trick pony (ADC formerly TAP technology not withstanding)
Not sure why earnings matter at this point. IMGN sold most of their upcoming earnings to speculate on the future. I mean, I guess good earnings point to the possibility of getting profit from Kadycla after the $200 mil mark, but the share price should be moving on trial results almost exclusively from here on out. I'm in, and I like the plan. And, yes, the recent move is lovely. Fingers crossed for continued success.
being more up than down is kind-of a new thing for this company.
hopefully this is a lasting trend and will keep going for at least a few months. The 50day moving average is trending up and looks to cross the 200 day moving average within the next month or so. Hopefully the dark ages for this company are now behind it and we can get some meaningful good news on the internal pipeline.
I've seen Crammer pump this stock and it maybe helps for a day or two. Won't get fooled again.